1. Home
  2. GOF vs EVO Comparison

GOF vs EVO Comparison

Compare GOF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Strategic Opportunities Fund of Beneficial Interest

GOF

Guggenheim Strategic Opportunities Fund of Beneficial Interest

HOLD

Current Price

$12.65

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.12

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOF
EVO
Founded
2006
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GOF
EVO
Price
$12.65
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
789.2K
251.3K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
15.42%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.96
$2.84
52 Week High
$16.76
$5.00

Technical Indicators

Market Signals
Indicator
GOF
EVO
Relative Strength Index (RSI) 59.80 50.32
Support Level $12.09 $3.03
Resistance Level $12.21 $3.05
Average True Range (ATR) 0.13 0.09
MACD 0.11 0.03
Stochastic Oscillator 99.26 80.42

Price Performance

Historical Comparison
GOF
EVO

About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest

Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: